Israel - English - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 18 miu/ml - solution for injection - interferon alfa-2b - chronic hepatitis b, chronic hepatitis c, hairy cell leukemia, chronic myelogenous leukemia, aids related kaposi`s sarcoma, malignant melanoma.treatment of metastatic or recurrent renal cell carcinoma non hodgkin`s lymphoma. treatment of high tumour burden follicular lymphoma as adjunct to apropriate combination induction chemotherapy such as a chop like regimen.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 80 mcg / 0.5 ml - powder for solution for injection - interferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 10 miu - solution for injection - interferon alfa-2b - - chronic hepatitis b. - chronic hepatitis c. - hairy cell leukaemia. - chronic myelogenous leukaemia. - multiple myeloma. - folicular lymphoma. - carcinoid tumour. - malignant melanoma.

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - interferon alfa-2b - injection - 18 miu/pen

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - interferon alfa-2b - injection - 30 miu/pen

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - interferon alfa-2b - carcinoid tumor; leukemia, hairy cell; lymphoma, follicular; hepatitis b, chronic; hepatitis c, chronic; leukemia, myelogenous, chronic, bcr-abl positive; melanoma; multiple myeloma - immunostimulants, - chronic hepatitis btreatment of adult patients with chronic hepatitis b associated with evidence of hepatitis-b viral replication (presence of dna of hepatitis-b virus (hbv-dna) and hepatitis-b antigen (hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and / or fibrosis.chronic hepatitis cbefore initiating treatment with introna, consideration should be given to the results from clinical trials comparing introna with pegylated interferon.adult patientsintrona is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for hepatitis-c virus-rna (hcv-rna).the best way to use introna in this indication is in combination with ribavirin.children three years of age and older and adolescentsintrona is indicated, in a combination regimen with ribavirin, for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that resulted in reduced final adult height in some patients.the decision to treat should be made on a case-by-case basis.hairy-cell leukaemiatreatment of patients with hairy cell leukaemia.chronic myelogenous leukaemiamonotherapytreatment of adult patients with philadelphia-chromosome- or bcr/abl-translocation-positive chronic myelogenous leukaemia.clinical experience indicates that a haematological and cytogenetic major / minor response is obtainable in the majority of patients treated. a major cytogenetic response is defined by < 34 % ph+ leukaemic cells in the bone marrow, whereas a minor response is ≥ 34 %, but < 90 % ph+ cells in the marrow.combination therapythe combination of interferon alfa-2b and cytarabine (ara-c) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.multiple myelomaas maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.follicular lymphomatreatment of high-tumour-burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a chop-like regimen. high tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°c for more than eight days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.carcinoid tumourtreatment of carcinoid tumours with lymph node or liver metastases and with 'carcinoid syndrome'.malignant melanomaas adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence, e.g. patients with primary or recurrent (clinical or pathological) lymph-node.

European Union - English - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

Canada - English - Health Canada

avondale (brinny) chemical company - interferon alfa-2b - liquid - 3000000unit - interferon alfa-2b 3000000unit - antineoplastic agents

Canada - English - Health Canada

avondale (brinny) chemical company - interferon alfa-2b - liquid - 5000000unit - interferon alfa-2b 5000000unit - antineoplastic agents

Canada - English - Health Canada

avondale (brinny) chemical company - interferon alfa-2b - liquid - 10000000unit - interferon alfa-2b 10000000unit - antineoplastic agents